We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Says ‘No’ to Opdivo for Lung Cancer Patients
The UK’s National Institute for Health and Care Excellence says it will not recommend Bristol-Myers Squibb’s Opdivo, casting doubt on the drug’s cost-effectiveness for people with locally advanced or metastatic non-squamous, non-small-cell lung cancer after chemotherapy.